Aarti Drugs Ltd. Share Price & Stock Analysis

Aarti Drugs Ltd. (BSE: 524348) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹4,650 Cr, it ranks #866 by market cap among the 6,197 Indian listed companies on FinBizNet, and #28 of 86 in Medicinal Chemicals and Botanical Products. At ₹506.00 (as of 16 Nov 2026), the share price is 4.1% below its 52-week high of ₹527.50 and 58.6% above its 52-week low of ₹318.95. The share price is up 3.2% over one year and up 18.6% over three months.

Key Metrics

Current Price₹506.00
Market Cap₹4,650 Cr
BSE Code524348
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio23.9
Return on Equity13.36%
Return on Assets5.62%
52-Week Range₹318.95 – ₹527.50
1-Year Price Change+3.2%
3-Month Price Change+18.6%
Beta (1Y)0.23
Dividend Yield0.39%
HeadquartersMumbai, Maharashtra
Websitewww.aartidrugs.co.in

Latest Quarterly Results — Q2 FY27

Revenue₹826 Cr
Net Profit₹83 Cr
Net Margin10.0%
EPS (Basic)₹9.07
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Aarti Drugs Ltd. Quarterly Revenue and Profit Trend

Aarti Drugs Ltd. reported revenue of ₹826 Cr in Q2 FY27, up 26.6% from ₹653 Cr in Q2 FY26 and up 17.6% from ₹703 Cr in Q1 FY27. It posted a net profit of ₹83 Cr for the quarter, against a net profit of ₹45 Cr in Q2 FY26 (up 83.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹591 Cr (Q1 FY26) to ₹826 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹826 Cr₹83 Cr10.0%
Q1 FY27₹703 Cr₹50 Cr7.1%
Q4 FY26₹720 Cr₹55 Cr7.7%
Q3 FY26₹602 Cr₹41 Cr6.7%
Q2 FY26₹653 Cr₹45 Cr6.9%
Q1 FY26₹591 Cr₹54 Cr9.1%
Q4 FY25₹677 Cr₹63 Cr9.3%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 54.07% of Aarti Drugs Ltd.'s shares as of Sept 2026, against 54.72% in Sept 2025 (−0.65 percentage points). Delivery averaged 32.5% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Aarti Drugs Ltd.

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfon

Products and Services

1. Bulk Drugs-This segment manufactures and sells active pharmaceutical ingredients. 2. Others-This segment engages in the manufacture and sale of bulk drugs and its intermediates. 3. Pharmaceuticals-0

Business Segments

1. Pharmaceuticals-100%

Aarti Drugs Ltd. vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Aarti Drugs Ltd.₹4,650 Cr23.913.36%₹826 Cr+3.2%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Aarti Drugs Ltd.?

Aarti Drugs Ltd. is trading at ₹506.00, with a market capitalisation of ₹4,650 Cr.

Which sector does Aarti Drugs Ltd. belong to?

Aarti Drugs Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Aarti Drugs Ltd.?

Aarti Drugs Ltd. has a P/E of 23.9 and a return on equity of 13.36%.

What is the stock symbol of Aarti Drugs Ltd.?

Aarti Drugs Ltd. is listed on the BSE under the scrip code 524348.

How has Aarti Drugs Ltd.'s share price moved over the past year?

Aarti Drugs Ltd.'s share price is up 3.2% over one year and up 18.6% over three months. Its 52-week range is ₹318.95 to ₹527.50.

What were Aarti Drugs Ltd.'s latest quarterly results?

In Q2 FY27, Aarti Drugs Ltd. reported revenue of ₹826 Cr and net profit of ₹83 Cr, with basic EPS of ₹9.07 (consolidated, parsed from the company's exchange filing).

How have Aarti Drugs Ltd.'s revenue and profit changed over the past year?

Aarti Drugs Ltd. reported revenue of ₹826 Cr in Q2 FY27, up 26.6% from ₹653 Cr in Q2 FY26 and up 17.6% from ₹703 Cr in Q1 FY27.

What is the promoter holding in Aarti Drugs Ltd.?

Promoters held 54.07% of Aarti Drugs Ltd.'s shares as of Sept 2026, against 54.72% in Sept 2025 (−0.65 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.